Similar Posts
Pulsar Terminal — Complete User Guide (MT5 Utility Add‑On)
Pulsar Terminal — Complete Guide: How to Use Every Feature This is a detailed walkthrough of Pulsar Terminal, a utility add-on for MetaTrader 5. Whether you are a scalper, a swing trader, or managing a prop firm account, this guide covers everything you need to get started and master the terminal. Pulsar Terminal is available on…
Blog Post: GMI declines to 4 of 6; More US stocks at yearly lows than highs on Friday (96 vs. 74); but $QQQ is at 27th day of short term up-trend; $NVDA is no longer in RWB up-trend and looking weak, see daily GMMA chart
NVDA has now closed below all 12 moving averages. (Dotted line is close.) It has also failed to hold its green line. The GM is now at 4. The successful new high component is now negative and there were fewer than 100 new highs on Friday. Screenshot Related Source link
Buy the Dip in e.l.f. Beauty: Analysts Point to a New High
ELF e.l.f. Beauty $160.83 -27.12 (-14.43%) (As of 08/9/2024 ET) 52-Week Range $88.47 ▼ $221.83 P/E Ratio 72.45 Price Target $217.64 Valuation concerns and slowing growth led e.l.f Beauty NYSE: ELF shares to fall following its Q1 release, but this is a buy-the-dip opportunity. The results were better than expected, including increased market share and improved…
ET Alpha Wealth Summit: Will AI disrupt India’s growth story or accelerate it?
Indian market is at an important inflection point. While strong economic fundamentals continue to support the long-term growth story, rapid advances in artificial intelligence are raising fresh questions about how industries, jobs and investment opportunities could evolve over the next decade. Against this backdrop, the ET Alpha Wealth Summit in Mumbai on June 4 will…
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
AbbVie NYSE: ABBV was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management’s lean toward diversifying away from Humira and into a broader range of treatments has more than paid off. The takeaway is that growth is back in the immunology portfolio despite the 30% contraction in…
